Annexon Biosciences Inc. (San Francisco, California, USA) has raised $75 million investment to fund development of its lead complement inhibitors through several clinical stages, according… Read More »Annexon Biosciences Inc. has raised over $75M investment to build classical complement pathway treatments
Applied Genetic Technologies Corporation (NASDAQ: AGTC), a gene therapy company, indicated that a treatment of a X-linked retinoschisis (XLRS) disorder has confirmed that interim six-month… Read More »Applied Genetic Technologies Corporation (ACGT Inc.) have terminated a gene therapy study for X-linked retinoschisis
Bayer and Novartis may appeal to a UK ruling on how Avastin (bevacizumab) will be allowed for doctors use lawful medication. The main crux of… Read More »Bayer and Novartis may appeal ruling in the UK on lawful use of Avastin (bevacizumab) for wet AMD
A commercial gene therapy company, Spark Therapeutics (NASDAQ:ONCE), announced that Committee for Medicinal Products for Human Use (CHMP), of the European Medicines Agency (EMA), has granted marketing authorization… Read More »The European Commission (EC) approves “Luxturna” (voretigene neparvovec), a recently developed gene therapy product to treat Leber congenital amaurosis (RPE65 mutations)
Editas Medicine, Inc. (NASDAQ: EDIT), based in Dublin, Ireland and Cambridge, Massachusetts, and Allergan plc (NYSE: AGN), also headquartered in Dublin, Ireland have announced the… Read More »Editas Medicine Inc. (NASDAQ:EDIT), and Allergan plc (NYSE:AGN), progress option rights to develop CRISPR technology for treatment of LCA 10
Novartis AG (NYSE:NVS; SIX:NOVN), a Swiss-based biopharmaceutical company, has announced its second quarter results showing net sales of $13.2 billion for the period, of which… Read More »Novartis Q2 results emphasize transition to a full “100% medicines company”
Nightstar Therapeutics (NASDAQ:NITE), originally a UK based spin-out of the University of Oxford, based on the founding work of Professor Robert MacLaren at the Nuffield… Read More »Nightstar Therapeutics, a UK-based clinical stage gene therapy company, receives US FDA Regenerative Medicine Advanced Therapy (RMAT) designation
Novartis AG (NYSE:NVS; SIX:NOVN), a Swiss-based biopharmaceutical company, has announced its intention to spin out its Alcon eye care business but will retain the pharmaceutical… Read More »Novartis announces spin out of Alcon unit to consolidate focus on pharmaceutical products.
Ophthotech Corporation (NASDAQ: OPHT), a US-based biopharmaceutical company focused on the development of retinal disease therapies, has announced the execution of agreements with both the… Read More »Ophthotech Corporation (NASDAQ:OPHT) announce agreements with two US universities to progress gene therapy for autosomal dominant retinitis pigmentosa (adRP)
Clearside Biomedical Inc. (NASDAQ:CLSD), head-quartered in Alpharetta, Ga., USA, have announced the results of a Phase II clinical study investiagting the use of triamcinolone acteonide… Read More »Clearside Biomedical Inc. study fails to show clinical significance of triamcinolone acetonide plus anti-VEGF treatment